SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff amid weakness in AI-infrastructure stocks has put its heavy debt burden, financing costs and insider selling at the center of the debate; a Goldman Sachs upgrade and reported ARK buying have not eased the concern for many traders. Bears warn of dilution or default, while bulls point to contracted AI-compute demand and see buying opportunities, leaving the stocks support levels in sharp focus.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders pointing to upcoming share unlocks, reported insider selling, and a TD Cowen price-target cut as sources of pressure. The debate is whether the decline is temporary supply and AI-sector weakness or reflects deeper concerns about customer concentration, growth, and valuation; some traders see an oversold opportunity while others expect further downside.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths quarterly earnings beat and raised full-year outlook, alongside improved medical-cost trends, are driving attention. Bulls view the results as evidence of a turnaround and welcome the rebound, while skeptics question whether the improvement will last and point to the stocks volatile reaction despite the strong report.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a sharp, prolonged pullback and a wider semiconductor selloff, with traders debating whether concerns about AI spending, financing, and returns signal a broader downturn. Many blame CEO Hock Tans comments likening AI investing to gambling for worsening sentiment, while others view the selloff as a buying opportunity.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff across AI-infrastructure stocks, fueled by concerns about neocloud financing, debt and whether heavy AI spending will generate sufficient returns. Traders are split on whether the rebound from oversold levels signals a recovery or a temporary bounce, with some arguing Nebius is better positioned than more debt-heavy peers.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile rebound after a broad AI and semiconductor selloff, as traders debate whether heavy AI infrastructure spending and debt financing can generate adequate returns. Bulls point to continued chip demand and company announcements, while skeptics warn of an AI spending bubble and further sector weakness.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers steep selloff is dominated by concerns that its convertible-note financing and added shares will dilute investors, alongside weakness across AI and data-center infrastructure stocks. Bears question management, debt and execution, while some holders see the decline as an oversold pullback and remain bullish on the companys longer-term AI hosting opportunity.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers recent climb toward a 52-week high and a key round-number resistance level is driving discussion, with traders highlighting bullish chart momentum and a defensive rotation into pharma. Others question whether the move can hold, pointing to resistance and the absence of a single clear near-term catalyst.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is under pressure at new lows, with traders linking the decline to Trumps falling approval and approaching midterms. Discussion is largely bearish, though a few see a speculative buying opportunity, while others point to concerns about the companys media-business fundamentals.

Aventus Network

Aventuss disclosure that an attacker exploited a code vulnerability to mint and sell AVT has fueled attention to the tokens sharp swings in thin markets; the team says the exploit is patched and the attacker has exited. Traders are split between hoping for a low-float rebound and worrying about concentrated holdings, supply changes, and persistent selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nateras run to fresh highs is drawing attention alongside the FDAs Breakthrough Device designation for its investigational multi-cancer early-detection assay and bullish analyst revisions. Traders are also debating whether the rally has stretched the valuation, with some citing continued growth and others expecting a pullback; the designation is not FDA approval.

ESMO 2026 Presentations Deepen the Evidence Base for Nateras Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 2326 in Madrid, Spain.New evidence...

Nateras Signatera MRD Test Named to TIMEs List of the Best Inventions of 2026

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIMEs Best Inventions of 2026 list, featuring extraordinary innovations that are changing lives.TIMEs Best Inventions...

Natera Gains 118.1% in a Year: What's Driving the Rally?

NTRA shares surge 118.1% in a year, fueled by robust Signatera adoption, expanding test volumes and improving margins, despite competition and rising costs.

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, today announced a strategic...

Tempus AI Expands Strategic Collaborations to Drive Future Growth

TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenue growth.

Natera Reports Q2 2026 Results: Full Earnings Call Transcript

On Thursday, Natera (NASDAQ:NTRA) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
Benzinga APIs provide real-time access to earnings call transcripts andread more...

FDA Grants Breakthrough Device Designation for Nateras Multi-Cancer Early Detection Assay

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food and Drug Administration (FDA). The BDD is designed for novel technologies...

Natera Announces Randomized, Signatera-Guided Interventional Study in Melanoma

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the enrollment of the first patients in a new Signatera-guided trial in melanoma (NCT07504796), sponsored by NYU Langone Health. The study uses Signatera to guide treatment escalation for patients...

New Signatera Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. The presentations marked Nateras first participation at ASTRO and a significant step in...

$1000 Invested In Natera 10 Years Ago Would Be Worth This Much Today

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 29.68% on an annualized basis producing an average annual return of 43.44%. Currently, Natera has a market capitalization of $62.06 billion.read more...

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Natera Inc

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Natera expects to commercially launch the test in Japan in the first half of 2027</li><li>Cantor sees Yartemlea potentially capturing 30% to 40% of its market over time.</li><li>Yartemlea generated $28.5 million in second-quarter net sales, nearly triple its first-quarter sales.</li></ul>Shares of Natera (NTRA) and Omeros (OMER) surged on Tuesday, hitting key milestones, after Natera secured regulatory approval in Japan for its cancer test and Cantor Fitzgerald upgraded Omeros amid growing optimism about its lead drug’s commercial potential.At the time of writing, <a href="https://stocktwits.com/symbol/OMER">OMER shares</a> were up 12% to their highest levels since March 2021, while <a href="https://stocktwits.com/symbol/NTRA">NTRA shares</a> climbed 5% to a record high.<h2 class="st-heading-2">Natera’s Cancer Test Receives Japanese Approval</h2>Natera said on Tuesday that its Signatera cancer test received regulatory approval in Japan as a companion diagnostic for patients with muscle-invasive bladder cancer. A companion diagnostic is a test approved for use with a particular treatment to help identify patients who may benefit from that treatment.In this case, the approval allows Signatera to help identify patients who may benefit from treatment with Roche’s Tecentriq immunotherapy after surgery.Natera expects to commercially launch the test in Japan in the first half of 2027.The approval came from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), the country’s regulator for drugs and medical devices. It marks Signatera’s second regulatory approval in Japan, following an approval as a companion diagnostic for colorectal cancer in June. Signatera has also been approved by the U.S. Food and Drug Administration (FDA) as a companion diagnostic in muscle-invasive bladder cancer.Retail sentiment surrounding NTRA on Stocktwits remained ‘bearish’ over the past 24 hours. NTRA shares have gained more than 70% year-to-date.<h2 class="st-heading-2">Cantor Sees Peak Sales Of $400M For Omeros’ Lead Candidate</h2>Omeros received an upgrade from Cantor Fitzgerald on Tuesday over optimism around its key drug, Yartemlea.According to The Fly, Cantor upgraded Omeros to ‘Overweight’ from ‘Neutral’ with a $22 price target. After speaking with physicians, the firm said it is “increasingly convinced” that the drug could become larger than previously expected, with the potential to capture 30% to 40% of its market. Cantor raised its peak sales estimate to $400 million.Yartemlea treats TA-TMA, a serious complication that can occur after stem-cell transplants. The FDA approved it in December 2025 as the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-serious-complication-stem-cell-transplant">first treatment</a> specifically approved for the condition.The drug generated $28.5 million in net sales in the second quarter, compared to $9.9 million in the first quarter.Retail sentiment surrounding OMER on Stocktwits turned to ‘neutral’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes. The stock has gained more than 26% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/cldx-stock-slumps-analyst-calls-phase-3-trial-safety-concerns-misplaced/cZMPHbZRB72">CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trending stock. (Photo Courtesy of Flavio Coelho via Getty Images)

Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea.

Omeros Corp

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$399.42
Prev Close	$393.44
Open	$401.47
Dividend Yield	0.00%
50-Day Moving Average	$359.63
Beta	1.31
Avg. Volume	1.54M
PE Ratio	-291.85

52-Week High	$437.41
52-Week Low	$181.00
Market Capitalization	$56.71B
EPS (Annual)	-$1.52
Price to Book	31.49
Revenue Per Employee	$375,588.44

Feed

News

Sentiment

Earnings

Fundamentals

Info

NTRA Fundamentals